Recent Quotes
My Watchlist
Indicators
REW 40 Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Celcuity Inc. - Common Stock (NQ:CELC)

105.63 -0.24 (-0.23%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Celcuity Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
The 7 Best Short-Squeeze Stocks to Buy Now: September 2023 ↗
Explore the potential of the best short-squeeze stocks to buy now as companies attempt to prove pessimistic traders wrong. 
Via InvestorPlace
News headline image
7 Short-Squeeze Stocks That Actually Might Make Sense ↗
Although the concept of short-squeeze stocks is one best left for speculators, these ideas have a touch of rationality behind them. 
Via InvestorPlace
News headline image
Preview: Celcuity's Earnings ↗
 
Via Benzinga
News headline image
10 Short Squeeze Stocks To Watch: Yellow Corporation, Getty Images, Tupperware And More ↗
Potential short squeeze plays gained steam in 2021, continued throughout 2022, and remain a new focus of traders looking for the next huge move. High short interest and steep borrowing costs are among... 
Via Benzinga
News headline image
Celcuity Set to Join Russell 2000 and 3000 Indexes
Via ACCESSWIRE
News headline image
A Preview Of Celcuity's Earnings ↗
 
Via Benzinga
News headline image
Celcuity's Earnings: A Preview ↗
 
Via Benzinga
News headline image
Celcuity to Participate in Upcoming Craig-Hallum and Jefferies Investor Conferences
Via ACCESSWIRE
News headline image
Celcuity Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Updates
Via ACCESSWIRE
News headline image
Celcuity Presents Updated Results from Phase 1b Study of Gedatolisib in Treatment-Naïve Patients at the 2023 ESMO Breast Cancer Annual Congress
Via ACCESSWIRE
News headline image
Celcuity Inc. Schedules Release of First Quarter 2023 Financial Results and Webcast/Conference Call
Via ACCESSWIRE
News headline image
Celcuity to Present Updated Results for Treatment-Naïve Patients from Phase 1b Study of Gedatolisib at the 2023 ESMO Breast Cancer Annual Congress
Via ACCESSWIRE
News headline image
Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Gynecological Cancer Models at AACR Annual Meeting 2023
Via ACCESSWIRE
News headline image
Celcuity to Participate in 22nd Annual Needham Virtual Healthcare Conference
Via ACCESSWIRE
News headline image
Celcuity Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Via ACCESSWIRE
News headline image
Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2022 Financial Results and Webcast/Conference Call
Via ACCESSWIRE
News headline image
Celcuity to Present Preclinical Data on Therapeutic Effects of Gedatolisib in Gynecological Cancer Models at AACR Annual Meeting 2023
Via ACCESSWIRE
News headline image
Earnings Scheduled For March 23, 2023 ↗
Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is likely to report earnings for its fourth quarter. 
Via Benzinga
News headline image
Celcuity to Participate in Cowen's 43rd Annual Health Care Conference
Via ACCESSWIRE
News headline image
Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Prostate Cancer at ASCO GU Cancers Symposium
Via ACCESSWIRE
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session ↗
Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial. 
Via Benzinga
News headline image
Celcuity Closes $100 Million Private Placement
Via ACCESSWIRE
News headline image
Celcuity Presents Updated Results of Phase 1b Study of Gedatolisib in Patients with Advanced Breast Cancer at the 2022 San Antonio Breast Cancer Symposium
Via ACCESSWIRE
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Celcuity Announces First Patient Dosed in Phase 3 VIKTORIA-1 Clinical Trial of Gedatolisib for the Treatment of HR+/HER2- Advanced Breast Cancer
Via ACCESSWIRE
News headline image
Celcuity to Present Additional Data for Gedatolisib at the 2022 San Antonio Breast Cancer Symposium
Via ACCESSWIRE
News headline image
Celcuity to Participate in the 13th Annual Craig-Hallum Alpha Select Conference
Via ACCESSWIRE
News headline image
Celcuity Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Via ACCESSWIRE
News headline image
Celcuity Inc. Schedules Release of Third Quarter 2022 Financial Results and Webcast/Conference Call
Via ACCESSWIRE
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.